Eli Lilly CEO Dave Ricks told CNBC that the company expects Medicare to begin covering obesity drugs immediately after the launch of its experimental pill orforglipron, potentially transforming patient access. With many early GLP-1 adopters currently paying cash for competitors’ products, immediate coverage could accelerate uptake among previously underserved populations. Lilly plans a full commercial rollout in the second quarter, timed to coincide with Medicare’s first‐ever obesity drug benefit under pricing agreements struck last November.

Lilly announced a $3.5 billion investment in a new Lehigh Valley manufacturing facility dedicated to next-generation obesity injections such as retatrutide. Construction is slated to begin this year, with operations targeted for 2031. The project will create 850 permanent roles—spanning engineering, laboratory and operations—and 2,000 construction jobs. This marks Lilly’s fourth new domestic site since 2020 and builds on a $27 billion capital commitment made in early 2025 to expand U.S. production capacity.

Despite a combined advertising outlay of approximately $214 million in 2025 on its obesity and diabetes franchises, Lilly has secured roughly 60% of the U.S. obesity drug market, according to IQVIA. Data from a late‐stage head-to-head trial showed Zepbound users achieved 47% greater weight loss than patients on Novo Nordisk’s leading injection, underlining Lilly’s competitive edge even against a rival spending more than twice as much on promotion.

The FDA has postponed its decision on orforglipron by nearly two weeks into the second quarter, tightening the window for approval ahead of Medicare coverage. Meanwhile, analysts highlight a premium forward P/E of 32.5x for the company and stress the need for exceptional tirzepatide performance in the upcoming Q4 results on February 4. Investors will be watching revenue contributions from weight-management therapies and guidance for 2026 to gauge whether valuation levels remain justified.